

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 4, 2010

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-50298
(Commission File Number)

98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: 972-2-566-0001

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01 REGULATION FD DISCLOSURE

On December 31, 2009, Oramed Pharmaceuticals Inc. issued a letter to its shareholders reviewing its achievements in 2009 and discussing the significant milestones for the beginning of 2010.

A copy of the letter is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

ITEM 7.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit Number	Description
99.1	Letter to shareholders dated December 31, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 4, 2009

ORAMED PHARMACEUTICALS INC.

By: /s/ Nadav Kidron
Nadav Kidron
President, CEO and Director

Exhibit Index

Exhibit Number	Description
99.1	Letter to shareholders dated December 31, 2009.



Dear Shareholder:

As we are about to begin 2010, I would like to take the opportunity to look back on the past year and note the progress that Oramed has made, and look at what is expected in the near future. Last year, beyond the actual clinical trials, Oramed was chosen to present at a number of significant scientific conferences, widening our exposure to the greater scientific community. Also, Oramed received a substantial grant from the Israeli Office of the Chief Scientist. In August 2009, Frost & Sullivan awarded Oramed with the 2009 European Oral Drug Delivery Technology Innovation Award. All in all this has been a very productive and exciting year for Oramed and we are hoping to move Oramed to the next level in 2010.

At the beginning of 2010, Oramed has significant milestones; which, if met successfully, will lead Oramed to new heights and take us a step closer to changing the paradigm for the treatment of Diabetes:

- **Results of Phase 2b clinical trials of Oramed's oral insulin capsule, being conducted in South Africa are expected at the end of the first quarter of 2010.** These trials mark one of the most important milestones to date for the drug, testing ORMD-0801 for the first time on a large group of volunteers for an extended duration.
- **Results are expected during the first quarter of 2010 from the first-in-human clinical study of ORMD-0901, an oral GLP1-analog.**
- IND submission for FDA approved Phase 2 clinical trials is expected in mid 2010.

On the public side, after keeping a relatively low profile, Oramed has recently engaged a new investor relations firm, Emerging Markets Consulting LLC (www.emergingmarketsllc.com /www.themicrocapreport.com) in order to enlarge the current investors cadre and expose Oramed to more investors. EMC will start providing its services to Oramed in early January 2010. Oramed is also considering hiring a new public relations firm to help expose the Oramed story to a broader audience.

On behalf of the entire Oramed team I wish you all a happy and successful year.

Best Regards,

Nadav Kidron,
Chief Executive Officer
